/PAVM

PAVM Stock - PAVmed Inc.

Q: What is the analyst price target for PAVM?

Analyst price target information is not currently available for PAVM.

Q: What is PAVM's market cap?

Market capitalization information is not currently available for PAVM.

Healthcare|Medical - Devices|NASDAQ

$0.31+10.14%

+$0.03 (+10.14%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.34

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PAVM

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.10

52W High$0.90

52W Low$0.27

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$3.00M	$2.45M	$377,000	$500,000	N/A
Gross Profit	$-3,043,000	$-3,968,000	$-3,237,000	$-85,000	N/A
Gross Margin	-101.6%	-161.8%	-858.6%	-17.0%	N/A
Operating Income	$-44,487,000	$-68,795,000	$-91,087,000	$-54,393,000	$-23,351,000
Net Income	$39.79M	$-64,175,000	$-88,983,000	$-50,347,000	$-34,276,000
Net Margin	1328.6%	-2617.3%	-23602.9%	-10069.4%	N/A
EPS	$3.30	$-9.16	$-15.03	$-9.80	$-10.93

Company Overview

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Visit Website

Earnings History & Surprises

PAVM

Beat Rate

37%

Last 19 quarters

Avg Surprise

-543.6%

EPS vs Estimate

Beats / Misses

7/12

Last 12 quarters

Latest EPS

$-0.28

Q4 2025

EPS Surprise History

Q1 24

+29.6%

$-1.33vs$-1.89

Q2 24

+40.7%

$-0.99vs$-1.67

Q3 24

+42.1%

$-0.84vs$-1.45

Q4 24

+58.5%

$-0.54vs$-1.30

Q1 25

+85.0%

$-0.06vs$-0.40

Q2 25

+75.9%

$-0.07vs$-0.29

Q3 25

+80.0%

$-0.05vs$-0.25

Q4 25

-40.0%

$-0.28vs$-0.20

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 24, 2026	$-0.20	—	—	—
Q4 2025	Nov 13, 2025	$-0.20	$-0.28	-40.0%	✗ MISS
Q3 2025	Aug 14, 2025	$-0.25	$-0.05	+80.0%	✓ BEAT
Q2 2025	May 15, 2025	$-0.29	$-0.07	+75.9%	✓ BEAT
Q1 2025	Mar 25, 2025	$-0.40	$-0.06	+85.0%	✓ BEAT
Q4 2024	Nov 13, 2024	$-1.30	$-0.54	+58.5%	✓ BEAT
Q3 2024	Aug 13, 2024	$-1.45	$-0.84	+42.1%	✓ BEAT
Q2 2024	May 13, 2024	$-1.67	$-0.99	+40.7%	✓ BEAT
Q1 2024	Mar 26, 2024	$-1.89	$-1.33	+29.6%	✓ BEAT
Q4 2023	Nov 14, 2023	$-0.14	$-1.35	-864.3%	✗ MISS
Q3 2023	Aug 15, 2023	$-0.19	$-1.35	-610.5%	✗ MISS
Q2 2023	May 16, 2023	$-0.21	$-1.50	-614.3%	✗ MISS
Q1 2023	Mar 14, 2023	$-0.25	$-2.25	-800.0%	✗ MISS
Q4 2022	Nov 15, 2022	$-0.26	$-2.25	-765.4%	✗ MISS
Q3 2022	Aug 16, 2022	$-0.23	$-2.55	-1008.7%	✗ MISS
Q2 2022	May 12, 2022	$-0.19	$-2.10	-1005.3%	✗ MISS
Q1 2022	Mar 29, 2022	$-0.15	$-2.25	-1400.0%	✗ MISS
Q4 2021	Nov 22, 2021	$-0.13	$-2.25	-1630.8%	✗ MISS
Q3 2021	Aug 12, 2021	$-0.10	$-1.20	-1100.0%	✗ MISS
Q2 2021	May 17, 2021	$-0.12	$-1.20	-900.0%	✗ MISS